GlassScriptPhysician profile
Sukhchain Samra
NPI 1073032447
$9,112.49
in general payments reported to CMS, 2019-2025
30 companies · $2,394 in 2025
The $2,394 reported for 2025 was more than what 95% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $378 · 2022: $1,027 · 2023: $2,406 · 2024: $2,907 · 2025: $2,394.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,308 · Education: $399.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,307.99 |
| Education | $399.04 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,920.29 | 2021-2025 | |
| Janssen Biotech, INC. | $1,691.31 | 2021-2025 | Tremfya, Simponi, Simponi Aria |
| Amgen INC. | $673.74 | 2021-2025 | Otezla, Otezla |
| E.R. Squibb & Sons, L.L.C. | $608.52 | 2022-2025 | Sotyktu |
| Dermavant Sciences, INC. | $580.37 | 2022-2024 | Vtama |
| Incyte Corporation | $548.67 | 2021-2025 | Opzelura, Monjuvi |
| Genzyme Corporation | $491.51 | 2021-2025 | |
| Janssen Scientific Affairs, LLC | $366.94 | 2022-2024 | Tremfya |
| Verrica Pharmaceuticals INC. | $328.18 | 2023-2024 | Ycanth |
| Sun Pharmaceutical Industries INC. | $294.86 | 2022-2025 | Winlevi, Ilumya |
| Organogenesis INC. | $256.39 | 2022-2023 | Puraply |
| Ucb, INC. | $242.79 | 2022-2025 | Bimzelx, Cimzia |
| Arcutis Biotherapeutics, INC. | $196.84 | 2024-2025 | Zoryve |
| Regeneron Healthcare Solutions, INC. | $150.54 | 2022-2025 | Dupixent |
| Novartis Pharmaceuticals Corporation | $133.01 | 2022-2025 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Leo Pharma INC. | $120.55 | 2024-2025 | Adbry, Anzupgo |
| Galderma Laboratories, L.P. | $118.55 | 2021-2025 | Nemluvio |
| Lilly USA, LLC | $82.89 | 2021-2025 | Taltz, Ebglyss, Jaypirca |
| Daiichi Sankyo INC. | $35.90 | 2024-2025 | Injectafer |
| Smith+Nephew, INC. | $35.31 | 2025 | Grafix Pl |
| Allergan, INC. | $32.39 | 2022 | |
| Geron Corporation | $30.62 | 2025 | Rytelo |
| Takeda Pharmaceuticals U.S.A., INC. | $30.57 | 2025 | Fruzaqla |
| Genmab U.S., INC. | $29.04 | 2025 | Epkinly |
| Celgene Corporation | $27.88 | 2025 | Opdivo |
| Astrazeneca Pharmaceuticals LP | $24.90 | 2025 | Imfinzi |
| Sobi, INC | $17.53 | 2025 | |
| Almirall LLC | $14.67 | 2023 | Seysara |
| Syndax Pharmaceuticals, INC. | $14.56 | 2025 | |
| Janssen Pharmaceuticals, INC | $13.17 | 2025 | Tremfya |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sukhchain Samra listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.